Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

T. K. Choueiri, R. J. Motzer, B. I. Rini, J. Haanen, M. T. Campbell, B. Venugopal, C. Kollmannsberger, G. Gravis-Mescam, M. Uemura, J. L. Lee, M. O. Grimm, H. Gurney, M. Schmidinger, J. Larkin, M. B. Atkins, S. K. Pal, J. Wang, M. Mariani, S. Krishnaswami, P. CisloA. Chudnovsky, C. Fowst, B. Huang, A. di Pietro, L. Albiges

Research output: Contribution to journal › Article › peer-review

297 Scopus citations

Fingerprint

Dive into the research topics of 'Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences